Chronic myelomonocytic leukemia
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- A myelodysplastic/myeloproliferative neoplasm which is characterized by persistent monocytosis, absence of a Philadelphia chromosome and BCR/ABL fusion gene, fewer than 20 percent blasts in the bone marrow and blood, myelodysplasia, and absence of PDGFRA or PDGFRB rearrangement.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Chronic myelomonocytic leukemia
- Therapeutic area
- Hematology
- chronic myelomonocytic leukemia
- CMML
- chronic myelomonocytic leukaemia (CMML)
- chronic myelomonocytic leukemia
- chronic myelomonocytic leukemia (CMML)
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0020311
- Parent condition
- MONDO:0001014
Related records
Broader conditions (31)
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Chronic leukemia
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system cancer
- Immune system disorder
Narrower conditions (1)
- Juvenile myelomonocytic leukemia
Trials (283)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 5-azacytidine Treatment Versus 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Myelodysplastic Syndrome (MDS)
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
- A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
- A Phase 1/2 Study of SB1518 for the Treatment of Advanced Myeloid Malignancies
- A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm
- A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
- A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes
- A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
- A Phase Ib/IIb, Open-label, Multi-center, Study of Oral Panobinostat Administered With 5-Azacitidine (in Adult Patients With Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML).
- A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- A Safety Study of Lintuzumab in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome
- A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia
- A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Approved drugs (2)
- Azacitidine
- Decitabine
Drugs in development (37)
- Aldesleukin Phase 3
- Alrizomadlin Phase 1
- Asparaginase Phase 3
- Busulfan Phase 3
- Cedazuridine Phase 1
- Clofarabine Phase 2
- Cobimetinib Phase 2
- Cyclophosphamide Phase 3
- Cytarabine Phase 3
- Daunorubicin hydrochloride Phase 3
- Dexamethasone Phase 3
- Epoetin beta Phase 2
- Etoposide Phase 3
- Filgrastim Phase 3
- Fludarabine Phase 2
- Fludarabine phosphate Phase 3
- Hydrocortisone Phase 3
- Idarubicin Phase 3
- Lenalidomide Phase 2
- Lenzilumab Phase 1